BIOEMTECH, a leader in high-resolution PET, has announced a strategic supply agreement with NorthStar Medical Radioisotopes to secure reliable access to Actinium-225 (Ac-225), a key alpha-emitting isotope for radiopharmaceutical development.

 

The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies, addressing a major bottleneck in early-stage radiopharmaceutical research and accelerating the evaluation of targeted therapies.

 

“We are pleased to partner with NorthStar Isotopes to strengthen access to Ac-225 for the preclinical research community,” said Dr Maritina Rouchota, Chief Quality Officer of BIOEMTECH. “Reliable isotope supply is a major bottleneck in early radiopharmaceutical development. This agreement enables our customers to run more predictable, higher-impact studies using our imaging platforms.”

 

Frank Scholz, President and CEO of NorthStar Medical Radioisotopes, added: “NorthStar is committed to expanding Ac-225 supply for the growing radiopharmaceutical market. Working with BIOEMTECH to support preclinical researchers aligns with our mission to advance global access to radiopharmaceuticals with dependable isotope supply with the required quality and regulatory standards.”

 

Key elements of the agreement include: Regular, scheduled Ac-225 deliveries tailored for preclinical dosing and research timelines; Validated quality and compliance with all regulatory and transport standards for research isotopes; Integrated research support, ensuring isotope delivery aligns with BIOEMTECH’s imaging services and customer timelines.

 

BIOEMTECH customers can request Ac-225 through the company’s ordering channels, while NorthStar will provide full isotope documentation and handling guidance to support laboratory safety and reproducible studies.